Showing 17,221 - 17,240 results of 27,815 for search '(( 12 men decrease ) OR ( 50 ((((mean decrease) OR (teer decrease))) OR (a decrease)) ))', query time: 0.83s Refine Results
  1. 17221

    Data_Sheet_1_Drug-Tolerant Idling Melanoma Cells Exhibit Theory-Predicted Metabolic Low-Low Phenotype.docx by Dongya Jia (3897142)

    Published 2020
    “…L/L metabolism is unfavorable for tumor growth, yet supports successful cell division at ~50% rate. Thus, L/L drug-tolerant idling cells are a reservoir for accumulating mutations responsible for relapse, and it should be considered as a target subpopulation for improving MAPKi outcomes in melanoma treatment.…”
  2. 17222

    Supplemental_Figure_of_Imeglimin_ameliorate_SA-AKI by Hiroyasu Goto (12227927)

    Published 2025
    “…Data are presented as the mean ± SE. Data were analyzed using a two-way analysis of variance (ANOVA) with Šidák’s post-hoc test #p<0.05. …”
  3. 17223

    Effect of environmental factors on the germination of Megathyrsus maximus: an invasive weed in sugarcane in Argentina by Debora C. Cabrera (10460723)

    Published 2021
    “…Both mean germination percentages and CG decreased as osmotic potential became increasingly negative (0 MPa to -0.6 MPa), and as sodium chloride solution concentrations increased (10 to 130 mmol L-1). …”
  4. 17224
  5. 17225

    The effects of purmorphamine and Msi1 knockdown on p21<sup>CIP1,WAF1</sup> and c-Myc expression. by In-Sun Hong (284033)

    Published 2013
    “…Purmorphamine treatment decreased and increased the expression of p21<sup>CIP1,WAF1</sup> (<b>A</b>) and c-Myc (<b>B</b>), respectively. …”
  6. 17226
  7. 17227
  8. 17228
  9. 17229
  10. 17230
  11. 17231
  12. 17232
  13. 17233

    Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain by Qiru Wang (12260453)

    Published 2024
    “…</p> <p>In experiments conducted on neuropathic rats, both systemic and intrathecal administration of astilbin, an essential constituent, exhibited a noteworthy and dose-dependently decrease in chronic and acute pain behaviours. …”
  14. 17234
  15. 17235

    Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts by Li Liu (75607)

    Published 2012
    “…The current study evaluated the vascular-disrupting activity of BPR0L075 in human breast cancer mammary fat pad xenografts using dynamic bioluminescence imaging. A single dose of BPR0L075 (50 mg/kg, intraperitoneally (i.p.)) induced rapid, temporary tumor vascular shutdown (at 2, 4, and 6 hours); evidenced by rapid and reproducible decrease of light emission from luciferase-expressing orthotopic MCF7 and MDA-MB-231 breast tumors after administration of luciferin substrate. …”
  16. 17236
  17. 17237
  18. 17238
  19. 17239
  20. 17240